MedOncMD

To provide the information your oncologist is not telling you or doesn't have the time to!

Clinical Trials

Dive into the heart of innovation with our “Clinical Trials” subcategory, where we unveil the dynamic world of oncology research in real-time. Discover the latest developments and breakthroughs in cancer treatment as we explore ongoing clinical trials and their potential impact on patient care. Gain insights into the rigorous process of testing novel therapies, uncover promising treatment options, and learn how these trials contribute to advancing the field of oncology. Stay informed and be part of the journey towards more effective and compassionate cancer care.

Esophageal Carcinoma: The Shift Towards Perioperative FLOT Therapy

For years, the treatment of esophageal carcinoma has been a subject of debate, with varying multimodal approaches tailored based on tumor location and staging. Traditionally, gastric cancer patients often underwent perioperative FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel) followed by surgical resection. Meanwhile, esophageal carcinoma patients were typically treated with neoadjuvant chemoradiotherapy (CROSS regimen: carboplatin/paclitaxel with radiation) followed by surgery or upfront chemotherapy …

Read On »

A New Frontier in Metastatic Colorectal Cancer Treatment: FDA Approval of Quad Therapy for BRAF V600E Mutation

On December 20, 2024, the FDA granted accelerated approval for a groundbreaking new treatment approach for patients with metastatic colorectal cancer (mCRC) harboring the BRAF V600E mutation. The newly approved regimen combines encorafenib (Braftovi) with cetuximab and mFOLFOX6 (a chemotherapy regimen consisting of fluorouracil, leucovorin, and oxaliplatin). This marks a pivotal step forward in the …

Read On »

Emerging Dual-Target Therapies in Multiple Myeloma: A Leap Forward in Treatment Outcome

Multiple myeloma, a complex and challenging hematologic malignancy, has seen remarkable advances in its treatment landscape. Standard care for transplant-eligible patients often involves quad therapy, blending immunomodulatory agents, proteasome inhibitors, anti-CD38 monoclonal antibodies, and corticosteroids. For frail or comorbid patients, triple therapy remains the mainstay. Hospitalized patients frequently benefit from CyBORD (cyclophosphamide, bortezomib, dexamethasone), and …

Read On »

Navigating Cancer Cachexia: Challenges, Treatments, and New Hope

Cancer cachexia is a debilitating condition that affects a significant portion of cancer patients, characterized by involuntary weight loss, muscle wasting, and metabolic dysfunction. Beyond its physical toll, cachexia diminishes quality of life and complicates cancer treatment, making it a critical issue in oncology. Despite its prevalence, effective treatments have been limited—until now. Recent advancements, …

Read On »

The Melanoma Milestone: Celebrating 10 Years of Immunotherapy Success

Stage IV melanoma used to be synonymous with a terminal diagnosis. For years, oncologists faced the grim reality of limited options and poor survival rates for their patients. However, the landscape has changed dramatically over the past decade. Breakthroughs in immunotherapy and clinical research have rewritten the narrative, offering hope to patients and their families. …

Read On »

A New Frontier in Frontline CLL Treatment: Fixed-Duration Acalabrutinib/Venetoclax Combination

The management of chronic lymphocytic leukemia (CLL), one of the most common types of leukemia, has advanced significantly over the past decade. New targeted therapies have reshaped treatment paradigms, providing effective, less toxic options compared to traditional chemoimmunotherapy. At the 2024 ASH Annual Meeting, data from the phase 3 AMPLIFY trial introduced another potential breakthrough …

Read On »

NEJM Study Highlights Breakthrough in MSI-High Colorectal Cancer Treatment with Ipilimumab and Nivolumab

Colorectal cancer remains a significant global health challenge, ranking as the third most common cancer and the second leading cause of cancer-related deaths worldwide. Among metastatic colorectal cancer patients, the subset with microsatellite instability-high (MSI-H) or mismatch-repair–deficient (dMMR) tumors presents unique opportunities for immunotherapy. The recent CheckMate 8HW trial, published in the New England Journal …

Read On »

Replimune’s RP1: A New Hope for Advanced Melanoma Patients

For patients with advanced melanoma who have exhausted standard treatment options, new therapies offer much-needed hope. On November 21, 2024, Replimune Group, Inc. announced that its breakthrough oncolytic immunotherapy, RP1 (vusolimogene oderparepvec), in combination with nivolumab, received Breakthrough Therapy Designation from the FDA. The FDA also accepted a Biologics License Application (BLA) for RP1 under …

Read On »

Reevaluating Radiation in Resectable Gastric Cancer: Insights from the TOPGEAR Trial

Radiation therapy has long been a cornerstone in the treatment of various cancers, including gastric cancer, particularly for locally advanced or high-risk cases. However, the evolving landscape of gastric cancer management has raised questions about the necessity of adding preoperative chemoradiotherapy to standard perioperative chemotherapy. The recently published TOPGEAR trial sheds new light on this …

Read On »

✕